Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of
In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of
Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026. After this transaction, he directly held 25,447 shares of Johnson & Johnson.
He also reported indirect holdings of 46 shares through an ESOP under the Johnson & Johnson Savings Plan and 745 shares through a 401(k), both based on the plan’s most recent reporting date of January 31, 2026.
Johnson & Johnson insider sale reported. The filing shows a sale of 22,623 common shares by Timothy Schmid on
Johnson & Johnson executive James D. Swanson reported a series of equity compensation transactions and related share sales. On February 13–17, 2026, he exercised employee stock options, restricted share units (RSUs), and performance share units (PSUs) into Johnson & Johnson common stock, with prices on certain option exercises around $162.75–$165.89 per share.
Swanson then conducted open-market sales totaling 62,080 shares of common stock at weighted average prices around $242.70–$243.76, while additional shares were withheld to cover tax obligations upon RSU and PSU vesting. Following these transactions, he directly owned 25,698.131 shares of Johnson & Johnson common stock.
Separately, on February 15, 2026, he received new equity awards under the company’s Long-Term Incentive Plan, including 19,449 employee stock options and 1,397 RSUs, which vest in three equal annual installments and convert into common stock on a one-for-one basis upon vesting.
Johnson & Johnson executive Kathryn E. Wengel, EVP and Chief TO and Risk Officer, reported multiple equity compensation transactions. She exercised vested restricted share units and performance share units into common stock on February 13 and 15, 2026, and received new grants of restricted share units and employee stock options under the company’s Long-Term Incentive Plan.
On those dates she acquired common shares through derivative exercises and awards, while a portion of the resulting shares was withheld at prices of $243.45 and $244.55 per share to cover tax obligations, which is disclosed as share dispositions. After these transactions, she held 113,977.8735 common shares directly, plus additional indirect holdings in the Johnson & Johnson Savings Plan and ESOP.
Johnson & Johnson EVP and Chief HR Officer Kristen Mulholland reported equity compensation activity involving restricted share units, performance share units, stock options, and common stock. On February 15, 2026 she received grants of 20,322 employee stock options and 1,459 restricted share units, all at a stated price of
On the same date, previously granted restricted share units converted into 419 and 575 shares of common stock, increasing her direct holdings. Some of these new shares were withheld at prices of about
On February 13, 2026, earlier grants of restricted share units and performance share units from prior years also converted into common stock. Those conversions added blocks of 410 and 3,602 common shares, followed by additional F-coded dispositions at around
JOHNSON & JOHNSON Executive VP and CFO Joseph J. Wolk reported multiple equity award transactions and sales. He exercised stock options, performance share units, and restricted share units into common stock on February 13, 15, and 17, 2026, and received new grants of 53,793 employee stock options and 3,863 restricted share units under the company’s long‑term incentive plan.
On February 17, 2026, he sold 89,654 shares of common stock in open‑market transactions and also disposed of shares to cover tax obligations upon vesting of awards. After these transactions, direct ownership entries show 14,000 common shares, alongside indirect holdings of 68,835 shares in a spousal lifetime access trust and 2,173 shares in a 401(k) plan.
Johnson & Johnson VP Corporate Controller Robert J. Decker reported multiple equity compensation transactions. On
On
Johnson & Johnson executive John C. Reed, EVP of Innovative Medicine R&D, reported multiple equity compensation transactions. He exercised employee stock options and restricted share units into common stock and received new awards of 49,382 employee stock options and 3,546 restricted share units under the company’s long-term incentive plan.
On February 17, 2026, he sold 53,931 shares of common stock in open-market transactions at a reported price of $243.0000 per share, following option exercises at lower exercise prices. The filing also shows shares withheld at $243.4500 per share to cover tax liabilities upon RSU vesting, and his remaining common stock holdings are reported as directly owned.